Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
2013; Elsevier BV; Volume: 122; Issue: 23 Linguagem: Inglês
10.1182/blood-2013-06-507319
ISSN1528-0020
AutoresMarco Ladetto, Chiara Lobetti‐Bodoni, Barbara Mantoan, Manuela Ceccarelli, Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonio Pinto, Sara Galimberti, Alessia Bari, Delia Rota‐Scalabrini, Angela Ferrari, Francesco Zaja, Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi, Enrica Gamba, Andrea Evangelista, Umberto Vitolo,
Tópico(s)CNS Lymphoma Diagnosis and Treatment
ResumoKey Points PCR negativity is a strong outcome predictor after rituximab-intensive immunochemotherapy at multiple posttreatment times. PCR is predictive even when maintenance is delivered, and accumulation of PCR-negative results further reduces the likelihood of relapse.
Referência(s)